NCT07570316ClinicalTrials.gov
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
باختصار
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is…
المرحلة 3مطلوب 230 مشاركاً35 موقعاً3 دول
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07570316فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل أسبوعين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-05-06; recorded start 2026-06-10
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 87 other studies in this databaseCounted from the lead sponsor named in the record (argenx)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 18 sites
- Data monitoring committee0/7
Data monitoring committee not stated in the record
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 230 participants (target), run at 35 sites, across 3 countries.
How this score is built
- Enrolment23/40
230 participants (target)
- Site count15/25
18 sites
- Country count7/15
2 countries
- Planned duration9/10
Planned over about 47 months
- Sponsor scale7/10
argenx has led 83 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy
الحالات
- Graves' Disease
- Graves Disease
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 3 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 230 مشاركاً |
الجهة الراعية والمتعاونون
- argenx الجهة الراعية
الأذرع والتدخلات
- Part A - efgartigimod PH20 SC PFSEXPERIMENTAL
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
- Part A - placebo PH20 SC PFSPLACEBO_COMPARATOR
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
- Part B - efgartigimod PH20 SC PFSEXPERIMENTAL
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
- Part B - placebo PH20 SC PFSEXPERIMENTAL
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
- Part C - efgartigimod PH20 SC PFSEXPERIMENTAL
Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period
التدخلات
- منتج بيولوجي Efgartigimod PH20 SC
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)
- أخرى Placebo PH20 SC
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)
مقاييس النتائج
مقياس النتيجة الأولي
Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Free triiodothyronine: \[fT3\]; free thyroxine: \[fT4\]; ATDs: antithyroid drugs
الإطار الزمني Up to 24 weeks (part A)
مقياس النتيجة الثانوي
Time to becoming euthyroid off ATDs in part A
ATDs: antithyroid drugs
الإطار الزمني Up to 24 weeks (part A)
مقياس النتيجة الثانوي
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A
MMI: methimazole (also known as thiamazole); CBZ: carbimazole.
الإطار الزمني Up to 24 weeks (part A)
مقياس النتيجة الثانوي
Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A
ULN : upper limit of normal; ATDs: antithyroid drugs.
الإطار الزمني Up to 24 weeks (part A)
مقياس النتيجة الثانوي
Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A
TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs.
الإطار الزمني Up to 24 weeks (part A)
مقياس النتيجة الثانوي
Time to becoming euthyroid off ATDs and TRAb seronegative
ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies.
الإطار الزمني Up to 24 weeks (part A) + up to 135 weeks
مقياس النتيجة الثانوي
Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)
ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole.
الإطار الزمني Up to 24 weeks (Part A)
مقياس النتيجة الثانوي
Time to becoming euthyroid
الإطار الزمني Up to 24 weeks (part A) + up to 135 weeks
مقياس النتيجة الثانوي
Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)
TSH: thyroid-stimulating hormone; LLN: lower limit of normal.
الإطار الزمني Up to 24 weeks (part A)
مقياس النتيجة الثانوي
Percentage of participants who remain euthyroid without ATDs
ATDs: antithyroid drug
الإطار الزمني Up to 74 weeks (part B)
مقياس النتيجة الثانوي
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months
ATDs: antithyroid drug
الإطار الزمني Up to 74 weeks (part B) + up to 135 weeks
مقياس النتيجة الثانوي
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS
ATDs: antithyroid drug
الإطار الزمني Up to 72 weeks (part C)
مقياس النتيجة الثانوي
Incidence of AEs and SAEs
AEs: adverse events ; SAEs: serious adverse events.
الإطار الزمني Up to 135 weeks
مقياس النتيجة الثانوي
Change in ThyPRO-39 over time
The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status.
الإطار الزمني Up to 135 weeks
مقياس النتيجة الثانوي
Change in PROMIS-PF10a over time
The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function.
الإطار الزمني Up to 135 weeks
مقياس النتيجة الثانوي
Efgartigimod serum concentrations over time
الإطار الزمني Up to 24 weeks (part A) + 72 weeks (part C)
مقياس النتيجة الثانوي
Percentage change from baseline in total IgG levels in serum over time
IgG: immunoglobulin G
الإطار الزمني Up to 98 weeks
مقياس النتيجة الثانوي
Percentage change from baseline in TRAb serum levels over time
TRAb: anti-TSHR autoantibodies.
الإطار الزمني Up to 135 weeks
مقياس النتيجة الثانوي
Incidence of ADA against efgartigimod in serum
ADA: antidrug antibody(ies)
الإطار الزمني Up to 24 weeks (part A) + up to 135 weeks
مقياس النتيجة الثانوي
Incidence of antibodies against rHuPH20 in plasma
rHuPH20: recombinant human hyaluronidase PH20
الإطار الزمني Up to 24 weeks (part A) + Up to 135 weeks
مقياس النتيجة الثانوي
Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma
NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20.
الإطار الزمني Up to 24 weeks (part A) + up to 135 weeks
التواريخ
| تاريخ البدء | 10 يونيو 2026 (فعلي) |
|---|---|
| الإتمام الأولي | 1 يونيو 2028 (تقديري) |
| الإتمام | 1 مايو 2030 (تقديري) |
| أول نشر | 6 مايو 2026 (فعلي) |
| آخر تحديث | 3 نوفمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | سبتمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
35 موقعاً قيد التجنيد
Georgia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| LLC American Hospital Network | Tbilisi | قيد التجنيد | |
| In Vitro Fertilization Center LLC | Tbilisi | قيد التجنيد | |
| LLC Todua Clinic | Tbilisi | قيد التجنيد | |
| New Hospitals | Tbilisi | قيد التجنيد | |
| LTD Israeli-Georgian Medical Research Clinic Healthycore | Tbilisi | قيد التجنيد |
United Kingdom
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust) | Gateshead | Tyne and Wear | قيد التجنيد |
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Albany Medical College Community Endocrinology | Albany | New York | قيد التجنيد |
| University of Michigan | Ann Arbor | Michigan | قيد التجنيد |
| Asheville Clinical Research | Asheville | North Carolina | قيد التجنيد |
| Profound Research LLC at Tri-City Primary Care | Carlsbad | California | قيد التجنيد |
| Research Institute of Dallas | Dallas | Texas | قيد التجنيد |
| Metro Detroit Endocrinology Center | Dearborn | Michigan | قيد التجنيد |
| Frontier Medical Center - Academy of Diabetes Thyroid and Endocrine | El Paso | Texas | قيد التجنيد |
| Profound Research | Farmington Hills | Michigan | قيد التجنيد |
| Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park Location | Fleming Island | Florida | قيد التجنيد |
| The Center for Diabetes and Endocrine Care | Fort Lauderdale | Florida | قيد التجنيد |
| Juno Research | Houston | Texas | قيد التجنيد |
| Clinic of Endocrinology | Houston | Texas | قيد التجنيد |
| Tekton Research Irving | Irving | Texas | قيد التجنيد |
| University of Florida Jacksonville College of Medicine | Jacksonville | Florida | قيد التجنيد |
| Truman Medical Center | Kansas City | Missouri | قيد التجنيد |
| Ilumina Medical Research LLC | Kissimmee | Florida | قيد التجنيد |
| Johnson County Clin-Trials, Inc. | Lenexa | Kansas | قيد التجنيد |
| Biopharma Informatic, LLC | McAllen | Texas | قيد التجنيد |
| Tekton Research - McKinney | McKinney | Texas | قيد التجنيد |
| Southern Endocrinology Associates PA | Mesquite | Texas | قيد التجنيد |
| Oceane 7 Medical & Research Center, Inc | Miami | Florida | قيد التجنيد |
| Endocrine Associates of West Village PC | New York | New York | قيد التجنيد |
| Diabetes Associates Medical Group | Orange | California | قيد التجنيد |
| Havana Research Institute LLC. | Pasadena | California | قيد التجنيد |
| Pasadena Clinical Trials | Pasadena | California | قيد التجنيد |
| Wake Internal Medicine Consultants | Raleigh | North Carolina | قيد التجنيد |
| San Jose Clinical Trials | San Jose | California | قيد التجنيد |
| Consano Clinical Research | Shavano Park | Texas | قيد التجنيد |
| Alliance for Multispecialty Research, LLC | Wichita | Kansas | قيد التجنيد |
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 3 نوفمبر 2026
أُضيف موقع
3 sites added (35 total)
3235
- 16 أكتوبر 2026
أُضيف موقع
6 sites added (32 total)
2632
- 22 سبتمبر 2026
أُضيف موقع
3 sites added (26 total)
2326
- 17 سبتمبر 2026
أُضيف موقع
1 site added (23 total)
2223
- 12 أغسطس 2026
أُضيف موقع
4 sites added (22 total)
1822